The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
A comprehensive meta-analysis from the University of Georgia has finally put major weight loss medications head-to-head. Here is what the data says about Zepbound, Wegovy, and Saxenda.
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
GLP-1 medications have revolutionized weight loss and diabetes management, but true metabolic health hinges on sustainable lifestyle changes. Discover how to improve your health, with or without these powerful tools.
Originally developed for diabetes, GLP-1 medications are now revealing profound insights into the neurobiology of desire, reward, and compulsion, impacting everything from food cravings to addictive tendencies.
A landmark study suggests semaglutide may protect bone strength while aiding weight loss, offering new hope for diabetes management and bone health.
A new study reveals BRP, a natural peptide, may offer the benefits of Ozempic without common side effects.
A comprehensive review of the latest clinical data comparing Tirzepatide, Semaglutide, and Liraglutide to determine the most effective option for significant weight reduction.
While known for diabetes and weight management, GLP-1 receptor agonists like Ozempic and Wegovy might have a surprising effect on impulse control and behavior, according to emerging research.
While GLP-1 agonists like Ozempic and Wegovy are celebrated for weight loss and blood sugar control, a recent study suggests a surprising benefit: improved bone health and a reduced risk of fractures in adults with Type 2 diabetes.
